Cargando…
A Case of Recalcitrant Prurigo Nodularis with Heightened Expression of STAT 3 and STAT 6 and its Dramatic Response to Tofacitinib
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373826/ https://www.ncbi.nlm.nih.gov/pubmed/37521237 http://dx.doi.org/10.4103/idoj.idoj_508_22 |
_version_ | 1785078643361316864 |
---|---|
author | Agrawal, Diksha Sardana, Kabir Mathachan, Sinu R. Ahuja, Arvind |
author_facet | Agrawal, Diksha Sardana, Kabir Mathachan, Sinu R. Ahuja, Arvind |
author_sort | Agrawal, Diksha |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-10373826 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-103738262023-07-28 A Case of Recalcitrant Prurigo Nodularis with Heightened Expression of STAT 3 and STAT 6 and its Dramatic Response to Tofacitinib Agrawal, Diksha Sardana, Kabir Mathachan, Sinu R. Ahuja, Arvind Indian Dermatol Online J Letter to the Editor Wolters Kluwer - Medknow 2023-05-25 /pmc/articles/PMC10373826/ /pubmed/37521237 http://dx.doi.org/10.4103/idoj.idoj_508_22 Text en Copyright: © 2023 Indian Dermatology Online Journal https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Letter to the Editor Agrawal, Diksha Sardana, Kabir Mathachan, Sinu R. Ahuja, Arvind A Case of Recalcitrant Prurigo Nodularis with Heightened Expression of STAT 3 and STAT 6 and its Dramatic Response to Tofacitinib |
title | A Case of Recalcitrant Prurigo Nodularis with Heightened Expression of STAT 3 and STAT 6 and its Dramatic Response to Tofacitinib |
title_full | A Case of Recalcitrant Prurigo Nodularis with Heightened Expression of STAT 3 and STAT 6 and its Dramatic Response to Tofacitinib |
title_fullStr | A Case of Recalcitrant Prurigo Nodularis with Heightened Expression of STAT 3 and STAT 6 and its Dramatic Response to Tofacitinib |
title_full_unstemmed | A Case of Recalcitrant Prurigo Nodularis with Heightened Expression of STAT 3 and STAT 6 and its Dramatic Response to Tofacitinib |
title_short | A Case of Recalcitrant Prurigo Nodularis with Heightened Expression of STAT 3 and STAT 6 and its Dramatic Response to Tofacitinib |
title_sort | case of recalcitrant prurigo nodularis with heightened expression of stat 3 and stat 6 and its dramatic response to tofacitinib |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373826/ https://www.ncbi.nlm.nih.gov/pubmed/37521237 http://dx.doi.org/10.4103/idoj.idoj_508_22 |
work_keys_str_mv | AT agrawaldiksha acaseofrecalcitrantprurigonodulariswithheightenedexpressionofstat3andstat6anditsdramaticresponsetotofacitinib AT sardanakabir acaseofrecalcitrantprurigonodulariswithheightenedexpressionofstat3andstat6anditsdramaticresponsetotofacitinib AT mathachansinur acaseofrecalcitrantprurigonodulariswithheightenedexpressionofstat3andstat6anditsdramaticresponsetotofacitinib AT ahujaarvind acaseofrecalcitrantprurigonodulariswithheightenedexpressionofstat3andstat6anditsdramaticresponsetotofacitinib AT agrawaldiksha caseofrecalcitrantprurigonodulariswithheightenedexpressionofstat3andstat6anditsdramaticresponsetotofacitinib AT sardanakabir caseofrecalcitrantprurigonodulariswithheightenedexpressionofstat3andstat6anditsdramaticresponsetotofacitinib AT mathachansinur caseofrecalcitrantprurigonodulariswithheightenedexpressionofstat3andstat6anditsdramaticresponsetotofacitinib AT ahujaarvind caseofrecalcitrantprurigonodulariswithheightenedexpressionofstat3andstat6anditsdramaticresponsetotofacitinib |